Long‐term outcome of prucalopride for chronic constipation: a single‐centre study

Rao, Pawan Kumar Dhruva; Lewis, Maria; Peiris, S. P. M.; Shah, PR; Haray, P. N.

doi:10.1111/codi.12993

Cited by 11 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sustained satisfaction with continued treatment with prucalopride was reported in two long-term open-label follow-up studies 48 that enrolled patients from three of the above-mentioned clinical trials 37–39 and in another open-label study. 49 However, the primary efficacy endpoint in these long-term studies was patient satisfaction evaluated using PAC-QOL, rather than improvement in SCBM frequency. Hence, a randomized placebo-controlled clinical trial was conducted to evaluate the efficacy of prucalopride over a 24-week period.…”

Section: Prucalopride: Clinical Evidence In Chronic Idiopathic Constimentioning

confidence: 99%

An update on prucalopride in the treatment of chronic constipation

Aras

Quigley

2017

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Chronic constipation (CC) is a highly prevalent and often under-appreciated gastrointestinal disorder associated with significant impairment in quality of life. Symptoms of constipation are typically present for a number of years prior to a patient seeking help. Lifestyle modifications followed by, or coupled with, over-the-counter laxatives represent the initial treatment option; however, relief for many is limited and dissatisfaction rates for these approaches remain high. Over recent years, therefore, considerable effort has been exerted on the development of novel pharmacological approaches. Two major targets have emerged, motility and secretion. Research on the former led to the development of a number of prokinetic agents capable of stimulating colonic motility and, thus, accelerating colonic transit. Of these, earlier prototypes such as cisapride and tegaserod, though effective, were ultimately withdrawn due to cardiovascular adverse events due in part to receptor nonselectivity. Highly selective serotonergic receptor agonists have since emerged which appear to be equally effective in stimulating gut motility but are devoid of cardiac side effects. One such agent is prucalopride, which has now been approved for the management of chronic idiopathic constipation in several countries, but not in the United States. Multiple multicenter, randomized placebo-controlled clinical trials have demonstrated superiority for prucalopride compared to placebo in the short to medium term in relieving the major symptoms of constipation in both men and women across a broad spectrum of ages, ethnicities and geographic locations. To date, prucalopride has enjoyed a favorable safety profile and there have been no signals to suggest arrythmogenicity. Efficacy over longer periods of treatment remains to be confirmed. Evidence for efficacy in other forms of constipation, such as opioidinduced constipation and that related to Parkinson's disease is beginning to emerge; its status in the management of constipation-predominant irritable bowel syndrome or foregut motility disorders, such as gastroparesis, remains to be established.

show abstract